CHLOROMYCETIN (chloramphenicol sodium succinate) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. First approved in 1959.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
CHLOROMYCETIN (chloramphenicol sodium succinate) is a broad-spectrum bacteriostatic antibiotic originally isolated from Streptomyces venezuelae, approved in 1959 for injectable use. It works by inhibiting bacterial protein synthesis through interference with amino acid transfer to ribosomes. The product is indicated for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms.
Product approaching loss of exclusivity with minimal linked commercial activity; team size and budget allocation likely constrained as Pfizer manages transition away from legacy antibiotic.
Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…
Worked on CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CHLOROMYCETIN represents a legacy portfolio management role with minimal career growth upside; the product faces LOE with zero linked job openings. Professionals in this space should expect portfolio consolidation, declining budgets, and eventual transition to post-LOE support or redeployment to growth franchises.